Sherlock S
Hepatology. 1984 Jan-Feb;4(1 Suppl):25S-28S. doi: 10.1002/hep.1840040709.
Chronic hepatitis is defined as diffuse chronic liver disease existing for at least 6 months. Cirrhosis is a sequel. It is of multiple etiology. Liver biopsy is essential for diagnosis and prognosis. Hepatitis B-related chronic hepatitis is slowly progressive. Corticosteroid therapy is disappointing. Current antiviral therapy converts the hepatitis B e antigen-positive patient to anti-HBe in about 50%. Non-A, non-B virus hepatitis-related chronic hepatitis suffers from lack of a diagnostic marker. No current therapy is of proven benefit. Autoimmune lupoid chronic active hepatitis presents a very active biochemical and immunological picture. Prednisolone therapy prolongs life but does not prevent the development of cirrhosis. Drug-related liver disease is recognized by its associations. Recovery follows withdrawal of the drug. Deaths often follow continuation of the drug. Indications of progression to a terminal state with likelihood of less than a 6-month survival are detailed. These are helpful in deciding on hepatic transplantation before the patient becomes moribund.
慢性肝炎被定义为持续至少6个月的弥漫性慢性肝病。肝硬化是其后续结果。病因多样。肝活检对诊断和预后至关重要。乙型肝炎相关的慢性肝炎进展缓慢。皮质类固醇疗法效果不佳。目前的抗病毒疗法可使约50%的乙肝e抗原阳性患者转为抗-HBe。非甲非乙型病毒肝炎相关的慢性肝炎缺乏诊断标志物。目前尚无经证实有效的治疗方法。自身免疫性类狼疮慢性活动性肝炎呈现出非常活跃的生化和免疫表现。泼尼松龙疗法可延长生命,但不能预防肝硬化的发生。药物性肝病可通过其相关情况得以识别。停药后可恢复。继续用药往往会导致死亡。详细说明了进展至终末期且存活可能性小于6个月的指征。这些对于在患者病情垂危之前决定是否进行肝移植很有帮助。